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Background: The biodiversity of the marine environment and the associated chemical diversity constitute a
practically unlimited source of new active substances in the field of the development of bioactive products. In our
study, we have investigated the efficiency of the venom from the Mediterranean jellyfish, Pelagia noctiluca and its
fractions for anti-proliferative and anti-cell adhesion to cell–extracellular matrix activities.
Results: Our experiments have indicated that the separation of the Mediterranean jellyfish Pelagia noctiluca crude
venom extract by sephadex G-75 chromatography led to four fractions (F1, F2, F3, and F4). Among the four
fractions F1 and F3 were cytotoxic against U87 cells with IC50 values of 125 and 179 μg/ml respectively. The
venom, F1, F2 and F 3 showed significant anti-proliferative activity in time-dependent manner. Our results also
suggest that these fractions and the venom are able to inhibit cell adhesion to fibrinogen in dose-dependent
manner. This inhibition is reliant on its ability to interact with integrins.
Conclusions: To conclude, we have demonstrated for the first time that Pelagia noctiluca venom and its fractions
especially (F1 and F2) display potent anti-tumoral properties. Separation by sephadex G-75 chromatography give
rise to more active fractions than the crude venom extract. The purification and the determination of chemical
structures of compounds of these active fractions are under investigation. Overall, Pelagia noctiluca venom may has
the potential to serve as a template for future anticancer-drug development.
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Gliomas are the most common form of brain tumour
[1]. Malignant gliomas are highly invasive, and as such,
are neurologically destructive. Survival rates are poor be-
cause present therapies, including surgery, radiation
therapy and chemotherapy, have limited effectiveness
[2]. Finding new therapeutic strategies targeting multiple
cell signaling pathways, such as inhibition of prolifera-
tion, adhesion, migration and angiogenesis, have been a* Correspondence: hassen-bacha@fmdm.rnu.tn
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reproduction in any medium, provided the ormajor point of concern for research in the pharmaceut-
ical sciences.
Extensive research has shown that cell-adhesion activ-
ities are deregulated in many diseases such as cancer.
Therefore, the characterization of molecules capable to
inhibit these alterations is considered very important for
the development of alternative therapies [3]. Snake
venoms are complex mixtures of molecules possessing
various biological functions. Researches have been
shown that several snake venom-derived peptides can
affect cell adhesion, proliferation and angiogenesis by
interacting with integrins[3,4].
Recently, the marine environment has been recognized
as a rich source of bioactive metabolites with varied bio-
logical and pharmacological activities [5-11]. Sometd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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darians. The most studied cnidarian compounds are the
secondary metabolites from soft corals such as diter-
penes, sesquiterpenes, terpenoids, and monoterpenoids
[12]. The jellyfish Pelagia noctiluca (P. noctiluca) [13],
(class Scyphozoa, order Semaestomeae, family Pelagii-
dae), is widely distributed in different parts of the Medi-
terranean Sea [14-16] and in the Atlantic Ocean [17].
Therefore, it is the most dangerous autochthonous
Mediterranean jellyfish [16], able to reconstitute its
stinging battery within few days after discharge [18].
Nematocysts (or cnidocysts) are characteristically used
by jellyfish to defend themselves against predator and to
capture prey. These organelles contain irritating poisons,
and are armed with sharp hollow threads that deliver
venom causing painful stings. Nematocysts are located
along the tentacles and body. Proteins isolated from
jellyfish, with a unique structure, have many bioactivities
such as enzymatic activities, hemolysin, dermonecrotic
factor, and cytolysin [16-19]. However, little is known
about the anti-tumor activity of the active components
of P. noctiluca venom and their mechanism of action on
cancer cells remains unknown.
Thus, this study attempts, for the first time to
characterize and evaluate the exact role of P. noctiluca
venom and its semi-purified fractions on (i) viability of
human glioblastoma cells (U87), (ii) cell proliferation
and (iii) cell adhesion to immobilized extracellular




bromide (MTT), Cell culture medium (RPMI1640),
foetal calf serum (FCS), phosphate buffer saline (PBS),
trypsin–EDTA, penicillin and streptomycin mixture and
l-glutamine (200 mM) were from GIBCO-BCL (UK).
Poly-L-lysine, Human fibrinogen was purchased from
Sigma (St Quentin Fallavier, France). All other chemicals
used were of analytical grade.
Preparation of nematocysts
Specimens of P. noctiluca were collected from the bay of
Monastir, Tunisia, in May 2011, and identified by profes-
sor Mohamed Nejib Daly Yahia from Faculty of Sciences
of Bizerte, (Bizerte, Tunisia). Tentacles were excised
manually from living specimens immediately after
capture.
The nematocysts isolation method has been previously
described by Arillo et al. [20] with a slight modification.
Tentacles were submerged in distilled water for 5 h at 4°C.
The ratio of organic tissue to distilled water was approxi-
mately 1:5 (v/v). After a complete detachment of the
epidermis, the tissue was removed from the suspensioncontaining both epidermis and undischarged nematocysts
deriving from the osmotic rupture of nematocysts. The
nematocysts, attached to the epidermal tissue, were
separated by stirring. The nematocysts suspension was
repeatedly washed in distilled water and filtered through
plankton nets to remove most of the tissue debris, and
then centrifuged at 4°C (ALC PK 120R, 4000 g for 5 min).
The content, purity and integrity of nematocysts
(cnidocysts) were controlled microscopically [21].
Nematocysts lysis and protein extraction
Crude venom was extracted by sonication on ice
(Sonoplus, 70 mHz, 30 times, 20 s) of nematocysts as
described by Marino et al. [21]. After sonication, the sus-
pension was centrifuged at 15,000 rpm for 15 min at 4°C.
The supernatant was carefully removed, filtered and
lyophilized.
Protein determination
The protein content of P. noctiluca venom was deter-
mined according to the Bradford method (BioRad Labs,
Hercules, CA) [22]. “venom and fractions concentra-
tions” refer to protein concentration expressed in units
of μg ml-1.
Size exclusion chromatography
About 300 mg of crude venom of P. noctiluca was
dissolved in filtered–degassed double-distilled water.
After centrifugation at 17 000 g for 15 min at 4°C, the
supernatant was loaded on Sephadex G-75 gel-filtration
chromatography columns (2.6 × 100 cm; Pharmacia), pre-
viously equilibrated with 200 mM ammonium acetate, pH
6.8 and eluted under the same conditions. The flow rate
was 3 ml/min using a Bio-Rad 2110 fraction collector and
the elution of the proteins was monitored at 280 nm by an
ultraviolet detector.
Cell viability assay
Cytotoxicity of P. noctiluca crude venom and its frac-
tions was defined using the colorimetric method
described by Mossmann, [16]. The MTT test assesses
cell metabolism based on the ability of the mitochondrial
succinate-dehydrogenase to convert the yellow com-
pound MTT to a blue formazan dye. The amount of dye
produced is proportional to the number of live metabol-
ically active cells.
Cells were seeded on 96-well culture plates (Polylabo,
France) at 105 cells/ well and treated with increasing
concentrations of crude venom extract at 37°C. After
24 h, the culture medium was replaced by 200 μl
medium containing 0.5 mg/ml MTT and the plates were
incubated 3 hours at 37°C. The medium was then removed
and replaced by 200 μl of (0,04 M HCl/isopropanol) to
solubilize the converted purple dye in culture plates. The
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plate reader (Dynatech 4000) at 560 nm.
Cell viability was expressed as the relative formazan
formation in treated samples as compared to control
cells (untreated cells) [(A560 treated cells/A560 control
cells) 100%]. IC50 values are defined as the concentra-
tion that induces 50% loss of cell viability.
For morphological analysis, U87 cells were treated
with 50 and 100 μg/ml of P. noctiluca crude venom or
F1 or F2 or F3 or F4. Morphological changes were
examined and recorded under an inverted phase con-
trast microscope (Olympus IX50 with a PMC35Dx
photo micrograph system). Each experiment was per-
formed in triplicates.Cell proliferation assay
U87 cells were plated (3× 103/well) in 96-well plates
(Nunc, Denmark) in their complete medium and were
incubated for 24 h before addition of P. noctiluca venom
and its fractions. After the incubation, the normal medium
was replaced for an extract containing medium at the con-
centrations of 10 μg/ml and treated for 48, 72, 96, and
120 h. The control cells were maintained in normal
medium.
The effect of tested compounds on proliferation of
U87 cell line was determined using the MTT assay
(previously described). Absorbance of the colored so-
lution was measured on a microplate photometer
(Dynatech 4000) using a wavelength of 560 nm. The
anti-proliferative effect of the tested extracts was
determined by comparing the optical density of the
treated cells against the optical density of the control
(untreated cells).Figure 1 Gel filtration chromatography of P. noctiluca crude venom o
3 ml aliquots were collected. Four fractions and two major peaks were obtCell adhesion assay
The human glioblastoma (U87) cell line was routinely cul-
tured in RPMI (GIBCO) medium with 10% FCS. Adhesion
assay was performed as previously described [23]. Briefly,
flat bottom 96-well microtiter plates were coated with one
of the following purified ECM proteins: 50 μg/ml fibrino-
gen (Fg) or poly-L-lysine (Poly-L) and were blocked with
BSA. Cells were harvested in single cell suspension and
resuspended in RPMI containing 0.2% BSA (adhesion buf-
fer) in the presence or absence of P. noctiluca crude
venom and its fractions. After incubation for 30 min at
room temperature, cells were added to coated wells in a
volume of 50 μl (106 cells/ml) and allowed to adhere with
the substrate for 1 h at 37°C in order to activate alpha v
beta 3 integrin. Unattached cells were removed by gently
washing three times with adhesion buffer. Residual
attached cells were fixed by 1% glutaraldehyde, stained by
0.1% crystal violet and lysed with 1% SDS. Absorbance
was then measured at 600 nm by a microplate reader.
Statistical analysis
All data are expressed as means ± standard error of the
mean (SEM) of at least 3 independent experiments. Stat-
istical differences were evaluated by 1-way ANOVA fol-
lowed by Tukey’s test using commercially available
software (SPSS 17.0; SPSS Inc., Chicago, Ill.). P values
<0.05 were considered statistically significant.
Results
Sephadex G-75 chromatography
Separation of crude venom of P. noctiluca was achieved
by a size exclusion chromatography (sephadex G 75).
This gel is a dextran capable of separating proteins with
molecular weights between 3 and 70 KDa. Proteins withn a Sephadex G75 column. Elution was performed at 18 ml/h and
ained.
Table 1 IC50 values of of P. noctiluca venom and its
fractions (F1- F4) on U87 cell line as determined by cell
viability and cell adhesion assays
Cell Viability Cell Proliferation Cell Adhesion
IC50(μg/ml) IC50(μg/ml)
Venom 180 ++ 25
F1 125 +++ 5
F2 - +++ 64
F3 179 + 100
F4 - - -
Effects of P. noctiluca venom and its fractions (F1- F4) on cell proliferation,
(−) no effect, (+) low, (++) medium, (+++) important.
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excluded.
The crude P. noctiluca venom (300 mg) was loaded on
a previously equilibrated Sephadex G-75 column
(2.6 × 100 cm; Pharmacia) after washing the column with
900 ml of 200 mM ammonium acetate buffer, pH 6.8.
The venom components were eluted with the same buf-
fer at a flow rate of 18 ml/h. Fractions were collected.
Protein elution was monitored at 280 nm and protein
contents were determined using the Bradford Method
[22]. The fractions obtained were grouped into four
groups and were pooled, lyophilized and evaluated in
U87 cell line (Figure 1).Inhibition of cell viability
The effect of crude venom of P. noctiluca and its fractions
(from the gel filtration chromatography) on cells viability
was assessed by the MTT assay [24]. Cultured cells were
exposed to increasing concentrations of crude venom of
P. noctiluca and its fractions for 24 h. As shown in Fig-
ure 1, all concentrations of crude venom (from 50 to
400 μg/ml) were sufficient to inhibit viability of U87 cells,
with a dose-dependent characteristic (Figure 2). IC50
value was about 180 μg/ml (Table 1). However, we
observed that all semi-purified fractions act differently on
cell viability. Reduction in the viability of U87 cells by F1
has been already significant at low concentrations and the
estimated IC50 was about 125 μg/ml. It indicates that F1
is more potent than the crude venom extract. A decrease
of cell viability was also observed when cells were treated
with F3, IC50 value was around 179 μg/ml (Table 1). F2
and F4 had no cytotoxic effect on U87 cells.
The morphological and growth characteristics were
assessed by observation of the cultures using an inverted
phase contrast microscope. Cells treated with crudeFigure 2 Cytotoxic effect of P. noctiluca crude venom and fractions (F
at the indicated concentrations for 24 h. Cell viability was determined usin
exposed to vehicle only. Control value was taken as 100%. Data are expres
cells).venom, F1 and F3 exhibited changes in their morph-
ology (Figure 3 ( )). During this incubation, a number
of cells was also detached from the culture flasks and died.Inhibition of cell proliferation
U87 cells were grown in 96-well assay plates and their
proliferation was measured over 5 days in four separate
independent experimental trials to determine if the ad-
ministration of P. noctiluca venom and its fractions at
10 μg/ml were sufficient to inhibit cellular proliferation.
Cells did not receive fresh medium during these periods
of incubation.
Our results demonstrated that comparison of treated
cells to untreated control cells at day 2 to day 5 revealed
that the venom, F1 and F2 had significant effect on cell
proliferation when applied at 10 μg/ml (P< 0.05, Fig-
ure 1). 120 h of incubation with venom or its fractions
were employed for U87 to demonstrate the extreme
cytotoxic effect of P. noctiluca venom and its fractions
on these cells. Despite the long period of incubation
(120 h) without adding fresh medium, untreated U871 –F4) on U87 cells. Cells were treated with venom and its fractions
g the MTT assay and expressed as percentages of control which was
sed as the mean ± S.E. *p< 0.05 compared with control (untreated
Figure 3 Effects of 50 and 100 μg/ml of P. noctiluca venom or its fractions (F1-F4) on U87 cell morphology in vitro. This figure
demonstrates that venom, F1 and F3 reduced cell growth when compared with untreated cells. Some cells displayed altered morphology (am).
Cells were observed with phase contrast microscope (original magnification × 100).
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of incubation.
As shown in Figure 4, F3 treatments slightly inhibited
glioma cells growth (of about 15%± 1.02). F4 had no ef-
fect since F4-treated cells were comparable to untreated
cells, whereas venom, F1 and F2 were more effective. In
particular, P. noctiluca venom at the same concentration
used for all tested compounds (10 μg/ml) induced a
64%± 1.06 reduction of cell growth rate after 120 h. F2
caused a consistent growth inhibition of about 45%± 1.6,
whereas the analysis of relative change in proliferation
between the control and F1 revealed that it caused the
largest reduction of cell survival, approximately
80%± 2.5. This decrease in cell survival was statistically
significant compared with the untreated control (p
< 0.05) (Figure 4). Treatment with F1 showed aninhibitory effect on cell proliferation similar to the
Treatment of cells with 5 μM Cisplatinum, a chemother-
apeutic drug known as potent cytotoxic agent on cancer
cell lines, used as a positive control. On the basis of
these results we decided to further investigate on the
anti-tumor activity of the venom and its active fractions.
Inhibition of cell adhesion
In a first set of experiments, we have assessed whether
P. noctiluca venom or its fractions exert an inhibitory ef-
fect on adhesion of U87 cells to purified ECM protein
used as substratum. Our results clearly showed that the
venom at a concentration of 50 μg/ml inhibited attach-
ment of the glioblastoma cell line to fibrinogen, U87 cell
adhesion to fibrinogen was also affected by F1, F2 and
F3 at a concentration of 50, 100 and 50 μg/ml
Figure 4 P. noctiluca venom or its fractions (F1-F4) inhibit tumour cells proliferation. U87 cells were cultured for the indicated periods of
time in the absence or in the presence of 10 μg/ml of venom or its fractions (F1-F4). Cell proliferation activity was evaluated by using MTT assay.
Measurement of the absorbance was performed at a wavelength of 560 nm. The results are from a representative experiment of two performed
in triplicate. *p< 0.05 compared with control (untreated cells).
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effect could be observed on the integrin independent
substratum, poly-L-lysine, suggesting that the effect of
the tested compounds indeed involved the integrin fam-
ily of adhesion receptors. At a concentration of 100 μg/
ml, F4 had no effect on the adhesion of U87 cells neither
to fibrinogen nor to poly-L-lysine (Figure 5).
In a second set of experiments, we measured the effect
of various concentrations of P. noctiluca venom or its
fractions (F1-F4) against U87 cell adhesion to fibrinogen
(Fg). As shown in Figure 6, the venom, F1, F2 and F3
inhibited the adhesion of U87 cells to fibrinogen. This
inhibition was dose-dependent, with an IC50 values of 5,
64 and 100 μg/ml respectively. We found that F4 did
not significantly affect U87 cells. According to this test,
the inhibitory effect of U87 cell adhesion to fibrinogen
ranking was F1>venom>F2>F3.Figure 5 U87 cells were preincubated without (control) or with 50, 50
for 30 min at room temperature. Cells were then added to 96-well micr
poly-L-lysine (Poly-L) and allowed to adhere for 1 h at 37°C. After washing,
and the absorbance was measured at 600 nm. **p< 0.01, ***p< 0.001 comDiscussion
As the toxicity of cnidarian venoms is a well-known sub-
ject [25], the aim of this paper is to demonstrate for the
first time that the venom of the jellyfish P. noctiluca, can
also exert anti-tumour activity in vitro.
Analysis of P. noctiluca venom on SDS-PAGE revealed
at least 15 protein bands ranging in molecular weights
from 4 to 120 kDa [26]. Sephadex G75 chromatography
led to the separation of the venom on four major
fractions.
The mechanisms of venom-induced cytotoxicity are
particularly interesting mainly for defining the concen-
tration range for further in vitro testing [27]. For this
purpose we have demonstrated that a decrease in cell
viability is moderately induced in U87 cells exposed to
crude venom extract of P. noctiluca in a dose-dependent
manner with an IC50 about 180 μg/ml (Figure 2,, 100, 50 and 100 μg/ml of venom, F1, F2, F3 and F4 respectively
otiter plates coated with 10 mg/ml with 50 mg/ml fibrinogen (Fg) or
adherent cells were fixed, stained with crystal violet, solubilized by SDS
pared with control (untreated cells).
Figure 6 Dose-effect of P. noctiluca venom and its fractions (F1-
F4) on U87 cell adhesion to fibrinogen. N= 4 (at least). Cell
adhesion towards fibrinogen was performed in the presence of the
indicated concentrations of P. noctiluca venom and its fractions (F1-
F4). Data shown
(± SD) are from one experiment representative of three performed
in triplicate. * indicates statistically significant differences (p< 0.05)
compared with the control (untreated cells).
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findings where P. noctiluca venom induced cell mortality
on Vero and HCT 116 cell lines [26-28].
After fractionation of P. noctiluca venom and screen-
ing of pooled fractions for cytotoxic activity, we
observed that F1 and F3 caused a market decrease of cell
viability in a concentration dependent manner. IC50
values determined after 24 h of cell treatments are
125 μg/ml and 179 μg/ml for F1 and F3, respectively
(Table 1). Whereas, F4 and F2 had no cytotoxic effect on
U87 cells (Figure 2).
As shown in Figure 3, the treatment of the crude
venom extract, F1 and F3 changed the cell morphology
of U87 cells from flattened glioblastoma membranous
morphology, representing activation state, to slender
shape, representing quiescent state (Figure 3 ( )).
Based on morphological change, we suppose that the
U87 cell mortality induced by P. noctiluca venom
extracts may be achieved by induction of apoptosis but
not due to direct toxic effect. To date, P. noctiluca
venom has been described to have a moderate cytotoxic
effects on cancer cell lines and was able to promote
apoptotic cell death on Vero cells [28].
One of the most frequent parameters assessed in can-
cer drug discovery is the impact of a given molecule on
the proliferation of a cancer cell [29]. For this reason the
effect of the crude venom extract and its fractions on
U87 cell proliferation were assessed using MTT assay
over a concentration of 10 μg/ml (This concentration is
about 17 times less cytotoxic than IC50) after 48, 72, 96
and 120 hours.
Our results has been shown a time-dependent increase
of the percentage of growth inhibition. The anti-
proliferative activity rates of P. noctiluca venom, F1, F2,F3 and F4 were about 60%, 80%, 50%, 20% and 5% re-
spectively after 5 days of exposure (Figure 4). Among
these results, crude venom, F1 and F2 appear to be the
most interesting fractions and exhibit an antiproliferative
effect comparable to that of the drug used clinically for
tumor treatment, cisplatinum (5 μM).
Similar to our results, Balamurugan et al. [30] reported
the antitumor activity of Chrysaora quinquecirrha
venom. Data revealed that a peptide with a molecular
weight of 9 kDa, isolated from Chrysaora quinquecirrha
venom by sephadex G-100 column chromatography
could induce apoptosis in HEp2 and HeLa cells [30].
This peptide was further studied in vivo for its anti can-
cer activity. Balamurugan et al. reported that nematocyst
venom of Chrysaora quinquecirrha peptide possessed
significant antitumor activity comparable to that of the
result obtained from the animals treated with the stand-
ard drug 5-fluorouracil [31].
Another study demonstrated that a potent cytolytic
proteins and an inhibitor of papain-like cysteine protei-
nases (equistatin), were isolated from the sea anemone
Actinia equina [32]. Equistatin has been shown to be a
potent inhibitor of papain and an inhibitor of the aspar-
tic proteinase cathepsin D [33]. Papain-like cysteine pro-
teases have been implicated in various diseases of the
central nervous system, such as brain tumors [34].
In addition to cell growth, treatment with P. noctiluca
extracts affected another hallmark of gliomas, i.e. adhe-
sion. According to our knowledge, such inhibitory activ-
ities of jellyfish venom on cell adhesion have not been
reported yet.
Cancer cells interact with their surrounding cells and
matrix proteins in order to replicate, gain nourishment,
and migrate to a new location. The interaction of cancer
cells with ECM is essential for metastasis, which is the
principal cause of death in cancer patients. Cancer cell
movement is controlled by various factors produced by
cancer cells and host cells, including growth and motility
factors, cytokines, cell adhesion molecules and ECM
proteins. Cell adhesion molecules play a crucial role in
cell motility through cell–cell and cell–ECM interactions
[35]. The most-characterized cell adhesion receptors are
the integrins. Integrins are cell adhesion molecules com-
posed by the noncovalent association of α and β subu-
nits. Thus, It has notably been shown that several snake
venom-derived peptides can affect integrin function.
Among these peptides, disintegrins have been widely
characterised and are now studied for potential use in
medicine [36].
Our findings clearly show that P. noctiluca venom
inhibited U87 cell adhesion to fibrinogen and had an
IC50 of 25 μg/ml. F1, F2 and F3 inhibited cell adhesion
to fibrinogen in a dose dependent manner with an IC50
of 5, 64 and 100 μg/ml respectively (Table 1). The
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ive when compared to the crude venom extract at the
same concentration. F4 was not able to inhibit cell adhe-
sion to fibrinogen. Moreover, no effect could be
observed on the integrin independent substratum, poly-
L-lysine, suggesting that the effect of P. noctiluca
extracts indeed involved the integrin family of adhesion
receptors (Figure 5). Thus, we hypothesized that crude
venom, F1, F2 and F3 could affect the function of this
family of adhesion receptors.
Preclinical data indicate that integrins play a key role
in cancer initiation and progression [37]. They are pri-
marily responsible for cell adhesion to ECM, and they
are thus involved in anchorage-dependent cell prolifera-
tion [38,39]. The integrins alpha V beta 3 and alpha V
beta 5, among others, are expressed not only on the
tumor vasculature and angiogenic endothelial cells, but
also on tumor cells, including gliomas (reviewed in [40]).
In glioblastoma, overexpression of alpha V beta 3 integ-
rin is well documented [41]. Importantly, immunohisto-
chemistry analysis revealed that alpha V beta 3 integrin
expression was mainly confined to the tumor region and
was absent in normal tissue [42].
Given the role of integrins in promoting glioma
growth, invasion and angiogenesis, integrin inhibitors
might be ideal therapeutic tools. Numerous anti-
angiogenic components targeting integrin receptors have
been isolated from snake venom [43]. These proteins be-
long to two families, disintegrins and C-type lectin pro-
teins. Since their initial characterization, snake venom
disintegrins have been extensively studied [44]. They are
potent and specific antagonists of several integrins, such
as alpha V beta 3 and alpha 5 beta 1, the disintegrin fam-
ily was the first to be characterized and the most exten-
sively studied [45]. EMS16, a C-type lectin protein from
Echis multisquamatus was the first example of a differ-
ent class of venom proteins showing an antagonistic ef-
fect on integrins [46]. In addition, BJcuL, from the snake
Bothrops jararacussu inhibits tumour and endothelial
cell growth [47] and Rhodocetin from Vipera
lebetina venom antagonises tumour invasion [4].
Conclusions
In conclusion, we isolated four fractions with sephadex
G-75 chromatography from venom of the Mediterranean
jellyfish P. noctiluca and evaluated their antiproliferative
activity separately using U87 cells. Among the four frac-
tions F1 and F2 and F 3 showed significant antiprolifera-
tive activity in time-dependent manner. Our results also
suggest that these fractions and the crude venom are
able to inhibit cell adhesion to fibrinogen in dose-
dependent manner. This inhibition is probably reliant on
its ability to interact with integrins. Although the spe-
cific integrins affected by P. noctiluca venom and itsactive fractions have not been identified in this study,
the integrin alpha V beta 3 and alpha 5 beta 1 might be
involved. The purification and the determination of
chemical structures of compounds of these active frac-
tions are under investigation. Overall, P. noctiluca
venom may has the potential to serve as a template for
future anticancer-drug development. Further analyses
are warranted and necessary to substantiate our findings.
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